Investors

At Alector, we are on a mission to slow the progression of neurodegenerative diseases and one day prevent their occurrence.

We are a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, we are advancing a differentiated portfolio of programs designed to remove toxic proteins, replace missing proteins, and restore neuronal function.

At the core of our strategy is the combination of Alector Brain Carrier (ABC), our proprietary blood-brain barrier platform, with deep knowledge in neuroscience, neurodegeneration and molecular engineering. We built a highly differentiated ABC platform with the versatility to delivery antibodies, enzymes, and siRNA to the brain. ABC is designed to enhance the delivery of therapeutics, achieve deeper brain penetration, and enable efficacy at lower doses, ultimately improving patient outcomes.

Our rich and growing pipeline of wholly owned ABC-enabled programs target a range of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and Lewy Body Dementia. We remain deeply committed to developing therapies that can make a meaningful difference for patients and their families.